Saiba AG focuses on a future COVID-19 vaccine with advantages over first to market vaccine candidates
Saiba AG has decided to focus on optimization of its vaccine candidate rather than rush into clinical studies in 2020.
Read MoreSaiba AG has decided to focus on optimization of its vaccine candidate rather than rush into clinical studies in 2020.
Read MoreGroup to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings Builds on positive ongoing progress in VLP-based peanut allergy candidate vaccine VLP platform to be combined with Allergy Therapeutics’ proprietary adjuvant technology Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy …
Read More